Virtus Biotech ETF

BBP · ETF

$102.07−$1.89 (−1.82%)TodayMarket closed · Oct 23, 8:00 PM ET

Prev close $103.96

Latest news

NewsMay 20, 8:49 AM ETVandana Singh
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug
NewsMar 26, 10:04 AM ETVandana Singh
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check
NewsMar 17, 1:54 PM ETVandana Singh
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use
NewsMar 13, 10:44 AM ETVandana Singh
Why Is ImmunityBio Stock Soaring On Friday?
NewsMar 9, 11:03 AM ETVandana Singh
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug
NewsFeb 17, 9:44 AM ETVandana Singh
Why Is ImmunityBio Stock Gaining Tuesday?
NewsApr 28, 12:17 PM ETLekha Gupta
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
NewsAug 19, 12:08 PM ETMichael Juliano
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use

Why Is ImmunityBio Stock Soaring On Friday?

ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug

Why Is ImmunityBio Stock Gaining Tuesday?

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch